Bacil Pharma

Why is Bacil Pharma Ltd falling/rising?

As of 20-Jun, Bacil Pharma Ltd's stock price is at 40.65, showing a short-term increase but significant long-term declines of 6.92% over one week and 22.19% over one month, alongside decreased investor participation. The stock is trading below its moving averages, indicating a bearish trend.

As of 20-Jun, Bacil Pharma Ltd's stock price is currently at 40.65, reflecting a slight increase of 0.11 (0.27%). The stock has shown a positive performance today, outperforming its sector by 1.74% and has been gaining for the last two days, with a total return of 6.14% during this period. <BR><BR>However, despite this recent uptick, the stock has experienced significant declines over longer periods, with a 1-week drop of 6.92% and a 1-month decline of 22.19%. Additionally, Bacil Pharma is trading below its moving averages across all time frames, indicating a bearish trend. The delivery volume has also decreased significantly, with a drop of 82.67% compared to the 5-day average, suggesting falling investor participation. <BR><BR>Overall, while there is a short-term rise in the stock price, the longer-term performance and declining investor interest indicate underlying challenges that may affect future price movements.

Which are the latest news on Bacil Pharma?

How big is Bacil Pharma?

As of 10th June, Bacil Pharma Ltd has a market capitalization of 72.00 Cr, with net sales of 0.00 Cr and a net profit of 1.34 Cr in the latest four quarters. Shareholder's funds are 25.43 Cr, and total assets amount to 25.55 Cr as of March 2025.

As of 10th June, Bacil Pharma Ltd has a market capitalization of 72.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Bacil Pharma reported net sales of 0.00 Cr and a net profit of 1.34 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with shareholder's funds amounting to 25.43 Cr and total assets of 25.55 Cr.

Who are in the management team of Bacil Pharma?

The management team of Bacil Pharma includes Prakash Shah, Ganpat Dhondu Salekar, Suman Shah (Directors), Shirish Shetye and Parul Dave (Independent Directors), and Bhavana Tak (Company Secretary & Compliance Officer).

The management team of Bacil Pharma includes the following individuals:<BR><BR>1. Prakash Shah - Director<BR>2. Ganpat Dhondu Salekar - Director<BR>3. Shirish Shetye - Independent Director<BR>4. Parul Dave - Independent Director<BR>5. Suman Shah - Director<BR>6. Bhavana Tak - Company Secretary & Compliance Officer<BR><BR>If you need more information about any specific member or their roles, feel free to ask!

Who are the peers of the Bacil Pharma?

Bacil Pharma's peers include Amwill Health, Makers Labs, Bharat Immunolog, Phaarmasia, Source Natural, Vilin Bio Med, Onyx Biotec, Zenith Drugs, and Ajooni Biotech. Notably, Phaarmasia has the highest 1-year return at 227.71%, while Source Natural has the lowest at -42.15%.

Peers: The peers of Bacil Pharma are Amwill Health, Makers Labs., Bharat Immunolog, Phaarmasia, Source Natural, Vilin Bio Med, Onyx Biotec, Zenith Drugs, and Ajooni Biotech.<BR><BR>Quality Snapshot: Excellent management risk is observed at Amwill Health and Source Natural, while Average management risk is found at Onyx Biotec, and the rest have Below Average management risk. Growth is Average at Phaarmasia and Vilin Bio Med, while Below Average growth is noted at Makers Labs., Bharat Immunolog, Phaarmasia, Source Natural, Zenith Drugs, and Ajooni Biotech. Capital Structure is Excellent at Amwill Health, Good at Source Natural and Ajooni Biotech, while Below Average capital structure is seen at Makers Labs., Bharat Immunolog, Phaarmasia, Vilin Bio Med, Onyx Biotec, and Zenith Drugs.<BR><BR>Return Snapshot: Phaarmasia has the highest 1-year return at 227.71%, while Source Natural has the lowest at -42.15%. Bacil Pharma's 1-year return of 23.76% is significantly higher than Source Natural's. Additionally, the six-month return is negative for Source Natural, Bharat Immunolog, and Zenith Drugs.

What does Bacil Pharma do?

Bacil Pharma Ltd is an Indian pharmaceutical company involved in the Pharmaceuticals & Biotechnology industry, with a market cap of INR 72 Cr and a recent net profit of 1 Cr as of March 2026. It was established in 1987 and became a public company in 1990.

Overview: <BR>Bacil Pharma Ltd is a fully integrated Indian pharmaceutical company operating in the Pharmaceuticals & Biotechnology industry, classified as a Micro Cap.<BR><BR>History: <BR>Incorporated as a private limited company in Maharashtra in May 1987, Bacil Pharma was converted into a public limited company in October 1990. The latest reported quarter for sales and profit is March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: 1 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 72 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 51.00 <BR>Industry P/E: 21 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.11 <BR>Return on Equity: 5.27% <BR>Price-to-Book: 2.93 <BR><BR>Contact Details: <BR>Address: 71 Laxmi Building, Sir P M Road Fort Mumbai Maharashtra : 400001 <BR>Phone: 91-022-22618452 <BR>Email: bacilpha@yahoo.com <BR>Website: http://www.bacilpharma.com

When is the next results date for Bacil Pharma Ltd?

The next results date for Bacil Pharma Ltd is 22 May 2026.

The next results date for Bacil Pharma Ltd is scheduled for 22 May 2026.

How has been the historical performance of Bacil Pharma?

Bacil Pharma has not generated revenue from March 2019 to March 2025 but improved its financial position by reducing total expenditure and achieving a profit after tax of 0.40 crore in March 2025, recovering from previous losses. Additionally, total assets increased significantly from 1.27 crore in March 2024 to 25.55 crore in March 2025, indicating better asset management.

Answer:<BR>The historical performance of Bacil Pharma shows a consistent lack of revenue generation over the years, with net sales and other operating income remaining at zero from March 2019 to March 2025. Despite this, the company has seen a significant improvement in its profit metrics, achieving a profit after tax of 0.40 crore in March 2025, a notable recovery from losses in previous years, including a loss of 3.86 crore in March 2022. The total expenditure has decreased from 3.92 crore in March 2022 to 0.25 crore in March 2025, indicating improved cost management. The company's total assets have increased dramatically from 1.27 crore in March 2024 to 25.55 crore in March 2025, primarily driven by a rise in non-current investments. <BR><BR>Breakdown:<BR>Bacil Pharma's financial history reveals a persistent absence of sales and operating income from March 2019 through March 2025, with total operating income consistently recorded at zero. However, the company has made strides in reducing its total expenditure, which fell significantly from 3.92 crore in March 2022 to 0.25 crore in March 2025. This reduction in expenses has contributed to a turnaround in profitability, as evidenced by the profit after tax reaching 0.40 crore in March 2025, compared to substantial losses in prior years. The company's total assets have surged from 1.27 crore in March 2024 to 25.55 crore in March 2025, largely due to an increase in non-current investments, reflecting a strategic shift in asset allocation. Overall, while Bacil Pharma has not generated revenue, its improved financial management and asset growth indicate a potential for future stability.

Is Bacil Pharma overvalued or undervalued?

As of November 17, 2023, Bacil Pharma is considered risky and overvalued with a PE ratio of 24.47 and a troubling ROCE of -13.29%, despite a strong one-year stock return of 70.54%, contrasting with a year-to-date decline of 27.35%.

As of 17 November 2023, Bacil Pharma's valuation grade has moved from does not qualify to risky, indicating a shift in its perceived financial health. The company appears to be overvalued given its current metrics, particularly with a PE ratio of 24.47, a Price to Book Value of 14.48, and a troubling ROCE of -13.29%. These figures suggest that the stock may not be justified at its current price level.<BR><BR>In comparison to its peers, Bacil Pharma's valuation stands out unfavorably; for instance, MMTC has a PE ratio of 119.39, while PTC India, which is rated very attractive, has a significantly lower PE of 9.02. The PEG ratio for Bacil Pharma is notably low at 0.03, which could indicate potential growth, but the negative EV to EBIT and EV to EBITDA ratios of -24.51 raise serious concerns about profitability. Despite a strong one-year stock return of 70.54%, the year-to-date performance shows a decline of 27.35%, contrasting sharply with the Sensex's positive return of 5.63% in the same period, reinforcing the notion that Bacil Pharma may be overvalued.

What is the technical trend for Bacil Pharma?

As of May 26, 2025, Bacil Pharma shows a mildly bullish trend due to daily moving averages and monthly MACD signals, but mixed indicators from weekly MACD and Bollinger Bands suggest caution.

As of 26 May 2025, the technical trend for Bacil Pharma has changed from does not qualify to mildly bullish. The current stance is mildly bullish, driven by a bullish signal from the daily moving averages and a bullish monthly MACD. However, the weekly MACD and Bollinger Bands indicate a mildly bearish sentiment, suggesting some caution. The KST is bearish on the weekly but bullish on the monthly, adding to the mixed signals. Overall, while there are bullish indicators, the presence of bearish signals in the weekly timeframe indicates a lack of strong momentum.